Anovulation
Drug research and approvals for anovulation: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 17, 2026, 7 studies of anovulation are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 1 approved and 0 open orphan designations naming it, and the EU has 6 authorised medicines for it.
- Recruiting worldwide: 7
- Trials authorized in Canada: 0
- FDA orphan approvals: 1
- EU medicines: 6
Recruiting Now
Newest start dates first, of 7 recruiting on ClinicalTrials.gov ↗- A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic AmenorrheaNCT07235917 · Phase 2 · Regeneron Pharmaceuticals · starts Mar 11, 2026
- Letrozole Extended vs Traditional Therapy for Ovulation Induction in Women With PCOS (PROLEx-PCOS)NCT07159880 · Not applicable · GABRIEL MONTEIRO PINHEIRO · starts Sep 1, 2025
- The REgistry of Very Early Estrogen and AnovuLationNCT06583408 · Not reported · Mayo Clinic · starts Jul 1, 2024
- Efficacy of Injectable Vitamin D Supplementation in Females With Polycystic Ovary SyndromeNCT06045351 · Phase 1 · Aga Khan University · starts Jan 1, 2024
- Sperm Preparation Prior to Intrauterine Insemination StudyNCT05693220 · Not applicable · University of California, San Francisco · starts Feb 5, 2023
- Effect of Vitamin D on Ovulation Rate in Women With Polycystic Ovary SyndromeNCT04650880 · Not applicable · The University of Hong Kong · starts Jan 26, 2021
- Autologous PRP Intra Ovarian Infusion to Restore Ovarian Function in Menopausal WomenNCT03916978 · Phase 2 / Phase 3 · Genesis Athens Clinic · starts May 21, 2019
Drug Pipeline
3 approved, 2 in phase 3, 4 in phase 2, 2 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Choriogonadotropin alfa, Follitropin alfa, Follitropin delta
- Follitropin
- Phase 3 Follicle stimulating hormone receptor agonist
- Urofollitropin
- Phase 3 Follicle stimulating hormone receptor agonist
- Clomiphene
- Phase 2 Estrogen receptor alpha modulator
- Gonadotropin, chorionic
- Phase 2 Luteinizing hormone/Choriogonadotropin receptor agonist
- Anastrozole
- Phase 2 Cytochrome P450 19A1 inhibitor
- Letrozole
- Phase 2 Cytochrome P450 19A1 inhibitor
- Paroxetine
- Phase 1 Serotonin transporter inhibitor
- Clarithromycin
- Phase 1 Bacterial 70S ribosome inhibitor
How Its Trials Ended
59 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 8 whose ending is known, 50% met their primary endpoint, 0% missed it and 50% stopped early.
- Completed, result not reported3458%
- Status unknown915%
- Ongoing814%
- Met its primary endpoint47%
- Stopped: other or unclear35%
- Stopped: sponsor or business decision12%
FDA Orphan Designations
Approved first, then open designations, newest first| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Oct 8, 2004 | LuverisLuveris (lutropin alfa for injection), concomitantly administered with Gonal-f (follitropin alfa for injection), is indicated for… | EMD Serono, Inc. | Approved |
Medicines Authorised in the EU
Newest first| Dec 12, 2016 | RekovelleFollitropin delta | Ferring Pharmaceuticals A/S | EMA ↗ |
| Mar 26, 2014 | BemfolaFollitropin alfa · biosimilar | Gedeon Richter Plc. | EMA ↗ |
| Sep 27, 2013 | OvaleapFollitropin alfa · biosimilar | Theramex Ireland Limited | EMA ↗ |
| Feb 2, 2001 | OvitrelleChoriogonadotropin alfa | Merck Europe B.V. | EMA ↗ |
| May 2, 1996 | PuregonFollitropin beta | Organon N.V. | EMA ↗ |
| Oct 20, 1995 | GONAL-fFollitropin alfa | Merck Europe B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA